as 05-20-2024 4:00pm EST
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Founded: | 1987 | Country: | United States |
Employees: | N/A | City: | GAITHERSBURG |
Market Cap: | 1.9B | IPO Year: | 1995 |
Target Price: | $14.00 | AVG Volume (30 days): | 12.9M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.13 | EPS Growth: | N/A |
52 Week Low/High: | $3.53 - $15.00 | Next Earning Date: | 05-10-2024 |
Revenue: | $996,609,000 | Revenue Growth: | -26.66% |
Revenue Growth (this year): | -11.9% | Revenue Growth (next year): | 9.36% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Dubovsky Filip | NVAX | President, R&D | May 14 '24 | Sell | $13.90 | 47,312 | $657,636.80 | 38,953 | SEC Form 4 |
NVAX Breaking Stock News: Dive into NVAX Ticker-Specific Updates for Smart Investing
MT Newswires
9 hours ago
Reuters
9 hours ago
GlobeNewswire
10 hours ago
Motley Fool
a day ago
Motley Fool
2 days ago
Zacks
3 days ago
Motley Fool
3 days ago
Zacks
4 days ago